Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. It offers BRINAVESS (vernakalant (IV)) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. The company also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension. It has operations in Canada, the United States, Europe, and internationally. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone604-677-6905
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees120
OptionableOptionable
Cardiome Pharma (NASDAQ:CRME) Frequently Asked Questions
What is Cardiome Pharma's stock symbol?
Cardiome Pharma trades on the NASDAQ under the ticker symbol "CRME."
How were Cardiome Pharma's earnings last quarter?
Cardiome Pharma Co. (NASDAQ:CRME) posted its earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.02. The biopharmaceutical company had revenue of $6.54 million for the quarter, compared to the consensus estimate of $7.34 million. View Cardiome Pharma's Earnings History.
What price target have analysts set for CRME?
2 analysts have issued 12-month price objectives for Cardiome Pharma's shares. Their predictions range from $5.00 to $10.00. On average, they expect Cardiome Pharma's share price to reach $7.50 in the next twelve months. View Analyst Price Targets for Cardiome Pharma.
What is the consensus analysts' recommendation for Cardiome Pharma?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardiome Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cardiome Pharma.
Has Cardiome Pharma been receiving favorable news coverage?
Media headlines about CRME stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cardiome Pharma earned a news sentiment score of -1.7 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next several days.
Who are some of Cardiome Pharma's key competitors?
Some companies that are related to Cardiome Pharma include Advanced Accelerator Application (AAAP), American Oriental Bioengineering (AOBI), Aralez Pharmaceuticals (ARLZ), ARMO Biosciences (ARMO), Bohai Pharmaceuticals Group (BOPH), Concordia International (CXRXD), Concordia International (CXRX), Depomed (DEPO), Egalet (EGLT), Eleven Biotherapeutics (EBIO), FutureWorld (FWDG), Impax Laboratories (IPXL), Juniper Pharmaceuticals (JNP), Oncolytics Biotech (ONCYF) and Orexigen Therapeutics (OREX).
Who are Cardiome Pharma's key executives?
Cardiome Pharma's management team includes the folowing people:
- Dr. William L. Hunter, Pres, CEO & Director (Age 55)
- Ms. Sheila M. Grant MBA, Chief Operating Officer
- Mr. David D. McMasters, Gen. Counsel (Age 59)
- Mr. Hugues Sachot, Chief Commercial Officer
- Mr. Justin A. Renz, Chief Financial Officer (Age 46)
How do I buy shares of Cardiome Pharma?
Shares of CRME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cardiome Pharma's official website?
How can I contact Cardiome Pharma?
Cardiome Pharma's mailing address is 1441 Creekside Drive 6th Floor, Vancouver A1, V6J 4S7. The biopharmaceutical company can be reached via phone at 604-677-6905 or via email at [email protected]
MarketBeat Community Rating for Cardiome Pharma (NASDAQ CRME)
MarketBeat's community ratings are surveys of what our community members think about Cardiome Pharma and other stocks. Vote "Outperform" if you believe CRME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRME will underperform the S&P 500 over the long term. You may vote once every thirty days.
